Blog
D-Wave Quantum's Q4 Bookings Fall Y/Y: How Does the Year Ahead Look?
D-Wave Quantum QBTS reported bookings of $13.4 million in the fourth quarter of 2025, down 27% compared to the prior-year period, which benefited from an eight-figure system sale. On a sequential
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue Estimates
TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.29 per share a year ago. These
The Real Brokerage Inc. (REAX) Reports Q4 Loss, Beats Revenue Estimates
The Real Brokerage Inc. (REAX) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to a loss of $0.03 per share a year ago. These
Is This the Right Time to Hold Labcorp Stock in Your Portfolio?
Labcorp Holdings Inc. LH, or Labcorp, is well-poised for growth in the coming quarters due to its test expansion in strategic high-growth areas, including neurology and autoimmune disease. The
3 Resilient Sales Growth Stocks for Navigating a Risk-Off Market
This year started on a weak note. U.S. markets have seen bouts of selling tied to shifting AI expectations and geopolitical tensions, especially Middle East risks and oil-shock fears, prompting
Riskified (RSKD) Q4 Earnings and Revenues Top Estimates
Riskified (RSKD) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.06 per share a year ago. These figures
Bath & Body Works (BBWI) Q4 Earnings and Revenues Surpass Estimates
Bath & Body Works (BBWI) came out with quarterly earnings of $2.05 per share, beating the Zacks Consensus Estimate of $1.77 per share. This compares to earnings of $2.09 per share a year ago. These
ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EU
Acadia Pharmaceuticals ACAD announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has formally adopted a negative opinion recommending
Should You Add These 3 Top-Performing Mutual Funds to Your Portfolio?
There is never a wrong time to invest in mutual funds for retirement. So, if you're still looking for the best mutual funds, the Zacks Mutual Fund Rank can be a great guide.
How can you tell a good
Make the Most of Your Retirement with These Top-Ranked Mutual Funds
It is never too late to invest in mutual funds for retirement. As such, if you plan to invest in some of the best funds, the Zacks Mutual Fund Rank can provide you with valuable guidance.
The
3 Great Mutual Fund Picks for Your Retirement
There is never a wrong time to invest in mutual funds for retirement. So, if you're still looking for the best mutual funds, the Zacks Mutual Fund Rank can be a great guide.
How can you tell a good
Are Europe ETFs at Threat Due to Iran Crisis?
A sustained spike in natural gas prices due to the escalating Middle East conflict could weigh heavily on European growth, analysts warn, as quoted on CNBC.
Global gas markets have rallied sharply
Intuitive Surgical Expands Direct Operational Presence in Europe
Intuitive Surgical ISRG has completed the acquisition of the da Vinci and Ion distribution business in Europe in a bid to start direct operations in the region. The company acquired the distribution
Stevanato Group (STVN) Surpasses Q4 Earnings and Revenue Estimates
Stevanato Group (STVN) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of $0.2 per share. This compares to earnings of $0.2 per share a year ago. These
Are Partnerships and Early Orders Powering Rigetti's Quantum Push?
Rigetti Computing RGTI is steadily positioning itself as a serious contender in scalable superconducting quantum computing, supported by a clear technology roadmap and a growing network of strategic
Vail Resorts to Report Q2 Earnings: What's in the Store for the Stock?
Vail Resorts, Inc. MTN is scheduled to report its second-quarter fiscal 2026 results on March 9, after the closing bell.In the last quarter, its adjusted earnings beat the Zacks Consensus Estimate
Here's Why You Should Retain Reliance Stock in Your Portfolio
Reliance, Inc. RS gains on growth through strategic acquisitions, its diversified business model and product base and strong liquidity amid headwinds from weakness in certain markets and
QUBT Q4 Earnings Match Estimates, Revenues Miss, Stock Slips
Quantum Computing Inc. QUBT, or QCi, delivered a loss of 4 cents per share in the fourth quarter of 2025 compared with a loss of 47 cents in the year-ago period. The metric came in line with the
Delek US Stock: Not a Buy, But Still Worth Holding for Now
Over the past six months, Delek US Holdings, Inc. DK has outperformed both the Oil Refining & Marketing sub-industry (ZSI128M) and the broader Oils & Energy sector (ZS12M). Delek's stock grew 28.4%
Pembina Pipeline Q4 Earnings and Revenues Beat Estimates
Pembina Pipeline Corporation PBA reported fourth-quarter 2025 earnings per share of 56 cents, which beat the Zacks Consensus Estimate of 50 cents. This improvement was primarily driven by strong
CF Industries' Stock Rallies 37% in 3 Months: Here's Why
CF Industries Holdings, Inc.’s CF shares have popped 36.5% over the past three months. The company has also outperformed the Zacks Fertilizers industry’s 40.7% decline over the same time frame. CF
National Vision (EYE) Surpasses Q4 Earnings and Revenue Estimates
National Vision (EYE) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to a loss of $0.04 per share a year ago. These
Wix.com (WIX) Q4 Earnings Top Estimates
Wix.com (WIX) came out with quarterly earnings of $1.81 per share, beating the Zacks Consensus Estimate of $1.36 per share. This compares to earnings of $1.93 per share a year ago. These figures are
BASFY Wraps Up OBA Transfer to Catexel, Advances Portfolio Shift
BASF SE BASFY recently announced the completion of the divestment of its Optical Brightening Agent (OBA) business to Catexel. The transaction was closed at the end of February 2026. The financial
Is Vanguard Target Retirement 2030 Fund (VTHRX) a Strong Mutual Fund Pick Right Now?
If you're looking for a Target Date fund category, then a possible option is Vanguard Target Retirement 2030 Fund (VTHRX). VTHRX has no Zacks Mutual Fund Rank, but we have been able to look into


